Publishing research using ab3573? Please let us know so that we can cite the reference in this datasheet.
ab3573 has been referenced in 7 publications.
Drolet B et al.Altered Protein Expression of Cardiac CYP2J and Hepatic CYP2C, CYP4A, and CYP4F in a Mouse Model of Type II Diabetes-A Link in the Onset and Development of Cardiovascular Disease?Pharmaceutics 9:N/A (2017).
PubMed: 29023376
Zhu J et al.Additive Neuroprotection of a 20-HETE Inhibitor with Delayed Therapeutic Hypothermia after Hypoxia-Ischemia in Neonatal Piglets.Dev Neurosci 37:376-89 (2015).
PubMed: 25721266
Zhang Y et al.Combined therapy with COX-2 inhibitor and 20-HETE inhibitor reduces colon tumor growth and the adverse effects of ischemic stroke associated with COX-2 inhibition.Am J Physiol Regul Integr Comp Physiol 307:R693-703 (2014).
WB
;
Mouse
.
PubMed: 24990856
Rector RS et al.Daily exercise vs. caloric restriction for prevention of nonalcoholic fatty liver disease in the OLETF rat model.Am J Physiol Gastrointest Liver Physiol 300:G874-83 (2011).
WB
;
Rat
.
PubMed: 21350190
Zhao X & Li LY PPAR-alpha agonist fenofibrate induces renal CYP enzymes and reduces blood pressure and glomerular hypertrophy in Zucker diabetic fatty rats.Am J Nephrol 28:598-606 (2008).
WB
;
Rat
.
PubMed: 18277067
Theve EJ et al.Sex hormone influence on hepatitis in young male A/JCr mice infected with Helicobacter hepaticus.Infect Immun 76:4071-8 (2008).
PubMed: 18559427
McCarthy ET et al.Protective effect of 20-hydroxyeicosatetraenoic acid (20-HETE) on glomerular protein permeability barrier.Kidney Int 67:152-6 (2005).
PubMed: 15610238
Please note: All products are "FOR RESEARCH USE ONLY AND ARE NOT INTENDED FOR DIAGNOSTIC OR THERAPEUTIC USE"
Get resources and offers direct to your inboxSign up